Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C

Medicine (Baltimore). 2020 Nov 25;99(48):e23384. doi: 10.1097/MD.0000000000023384.

Abstract

Hepatitis C virus (HCV) infection is very common in maintenance hemodialysis patients, causing high morbidity and mortality. This study aimed to evaluate the effectiveness and adverse events of direct-acting antivirals (DAAs) in maintenance hemodialysis patients complicated with chronic hepatitis C in real-world clinical practice.In this retrospective observational study, hemodialysis patients with chronic hepatitis C infection in the Third Central Hospital of Tianjin outpatient were screened, and appropriate treatment plans were selected accordingly. Totally 25 patients diagnosed with chronic hepatitis C and treated with DAAs for 12 weeks or 24 weeks were included. The sustained virologic response (SVR) rate obtained 12 weeks post-treatment (SVR12) was evaluated. Laboratory indexes and adverse reactions during the treatment process were also assessed.A total of 25 cases met the eligibility criteria and provided informed consent. Except for 1 patient who discontinued the treatment due to gastrointestinal bleeding, the remaining 24 cases completed the treatment cycle with 100% rapid virologic response (RVR) and 100% SVR12, with no serious adverse reactions recorded.Maintenance hemodialysis patients complicated with chronic hepatitis C in Chinese real-world setting tolerate DAAs very well, with a viral response rate reaching 100%.

Publication types

  • Observational Study

MeSH terms

  • Alanine Transaminase
  • Amides / administration & dosage
  • Amides / adverse effects
  • Antiviral Agents / administration & dosage*
  • Antiviral Agents / adverse effects
  • Aspartate Aminotransferases
  • Benzofurans / administration & dosage
  • Benzofurans / adverse effects
  • Carbamates / administration & dosage
  • Carbamates / adverse effects
  • Cyclopropanes / administration & dosage
  • Cyclopropanes / adverse effects
  • Drug Therapy, Combination
  • Female
  • Genotype
  • Hemoglobins / analysis
  • Hepacivirus / genetics
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Imidazoles / administration & dosage
  • Imidazoles / adverse effects
  • Isoquinolines / administration & dosage
  • Isoquinolines / adverse effects
  • Male
  • Middle Aged
  • Pyrrolidines
  • Quinoxalines / administration & dosage
  • Quinoxalines / adverse effects
  • RNA, Viral / blood
  • Renal Dialysis*
  • Renal Insufficiency, Chronic / complications*
  • Renal Insufficiency, Chronic / therapy
  • Retrospective Studies
  • Sofosbuvir / administration & dosage
  • Sofosbuvir / adverse effects
  • Sulfonamides / administration & dosage
  • Sulfonamides / adverse effects
  • Valine / analogs & derivatives
  • Viral Load

Substances

  • Amides
  • Antiviral Agents
  • Benzofurans
  • Carbamates
  • Cyclopropanes
  • Hemoglobins
  • Imidazoles
  • Isoquinolines
  • Pyrrolidines
  • Quinoxalines
  • RNA, Viral
  • Sulfonamides
  • grazoprevir
  • elbasvir
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Valine
  • daclatasvir
  • asunaprevir
  • Sofosbuvir